LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.37

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.31

Максимум

1.42

Ключови измерители
By Trading Economics
Приходи	-6.4M -56M
EPS	-0.92
Служители	171
EBITDA	7.9M -48M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+252.21% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-7.4M 90M
Предишно отваряне	1.37
Предишно затваряне	1.37

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.05.2025 г., 22:52 ч. UTC

Печалби

Значими двигатели на пазара

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15.05.2025 г., 20:37 ч. UTC

Топ новини

Печалби

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16.05.2025 г., 00:00 ч. UTC

Пазарно говорене

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15.05.2025 г., 23:47 ч. UTC

Пазарно говорене

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15.05.2025 г., 23:38 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

15.05.2025 г., 23:38 ч. UTC

Пазарно говорене

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15.05.2025 г., 23:14 ч. UTC

Топ новини

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15.05.2025 г., 22:46 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15.05.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15.05.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15.05.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15.05.2025 г., 21:58 ч. UTC

Печалби

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15.05.2025 г., 21:24 ч. UTC

Печалби

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15.05.2025 г., 20:56 ч. UTC

Пазарно говорене

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15.05.2025 г., 20:54 ч. UTC

Пазарно говорене

Печалби

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15.05.2025 г., 20:54 ч. UTC

Печалби

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15.05.2025 г., 20:51 ч. UTC

Печалби

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15.05.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

15.05.2025 г., 20:50 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15.05.2025 г., 20:50 ч. UTC

Печалби

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15.05.2025 г., 20:47 ч. UTC

Печалби

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15.05.2025 г., 20:47 ч. UTC

Печалби

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15.05.2025 г., 20:47 ч. UTC

Печалби

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15.05.2025 г., 20:47 ч. UTC

Печалби

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15.05.2025 г., 20:37 ч. UTC

Печалби

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15.05.2025 г., 20:37 ч. UTC

Печалби

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15.05.2025 г., 20:37 ч. UTC

Печалби

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15.05.2025 г., 20:37 ч. UTC

Печалби

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15.05.2025 г., 20:26 ч. UTC

Топ новини

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15.05.2025 г., 20:25 ч. UTC

Печалби

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

252.21% нагоре

12-месечна прогноза

Среден 4.79 USD 252.21%

Висок 17 USD

Нисък 1.5 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.